Text and Data Mining valid from 2019-04-18
First Online: 18 April 2019
: C.B.V. declares that she has received consultancy fees from Merck/EMD Serono. M.R. declares that he has received research funding from the US National Institute of Neurological Disorders and Stroke and the US National Science Foundation. R.H.B.B. declares that he has received research support from Accorda, Biogen, Genzyme, Mallinckrodt and Novartis; consultancy fees from Biogen, Genentech, Genzyme, Novartis, Roche, Sanofi and Teva; and compensation for activities relating to continuing medical education from EMD Serono. R.Z. declares that he has received speakers’ and consultancy fees from Celgene, Claret Medical, EMD Serono, Genzyme-Sanofi, IMS Health, Novartis and Roche-Genentech and financial research support from Claret Medical, IMS Health, Intekrin, Genzyme-Sanofi and Novartis. B.W.-G. declares that she has received fees for consultancy, acting as a speaker and serving on the scientific advisory boards of Biogen Idec, EMD Serono, Genzyme-Sanofi, Novartis, Questcor and Teva Neuroscience, and financial research support from Aspreva, Biogen Idec, EMD Serono, Genzyme, the Immune Tolerance Network Clinical Trials Group, the National Multiple Sclerosis Society, the NIH (not related to the present work), Novartis and Teva Neuroscience. D.J. and K.S.K. declare no competing interests.